Haobin Deng
Overview
Explore the profile of Haobin Deng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fu X, Zhang Z, Wang Y, Lu L, Chen T, Deng H, et al.
Front Med (Lausanne)
. 2024 Dec;
11:1503707.
PMID: 39635584
Ankle cartilage injuries are a common sports-related condition that significantly impairs patients' daily activities and imposes substantial economic burdens on both families and society. Effective cartilage repair strategies are crucial...
2.
Zhao T, Mu Y, Deng H, Liang K, Zhou F, Lin Q, et al.
Front Cell Dev Biol
. 2024 Nov;
12:1412363.
PMID: 39539963
Introduction: Our study aims to provide a comprehensive overview of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) in drug delivery research, focusing on the period between 2013 and 2023. Given the...
3.
Zhang M, Li H, Li Q, Yang Z, Deng H, Xu Y, et al.
Front Psychol
. 2024 Nov;
15:1457625.
PMID: 39512576
Depression is a common psychological complication in osteoarthritis (OA) patients, and its incidence gets more and more attention year by year worldwide. This study investigates the association between OA and...
4.
Lu R, Deng H, Guo X, Dai J, Gan P
Zhong Nan Da Xue Xue Bao Yi Xue Ban
. 2024 May;
49(2):273-278.
PMID: 38755723
Objectives: The repair of small and medium-sized defects in the oral has always been a challenge, free skin flap and distal pedicled tissue flaps are difficult to meet clinical needs,...
5.
Tan S, Deng J, Deng H, Lu L, Qin Z, Liu Y, et al.
Front Oncol
. 2023 Oct;
13:1253573.
PMID: 37781203
Objective: In the last three decades, there has been a surge in research on cancer organoids using 3D culture technologies, which has resulted in the development of physiological human cancer...
6.
Chen J, Jiang F, Zhao C, Chai J, Li L, Guan Q, et al.
Hum Vaccin Immunother
. 2023 Aug;
19(2):2245721.
PMID: 37587615
This study aimed to evaluate the immunogenicity non-inferiority and safety of the quadrivalent inactivated split-virion influenza vaccine in participants ≥ 3 years old. A total of 3,328 participants were enrolled....
7.
Mu J, Deng H, Lyu C, Yuan J, Li Q, Wang J, et al.
Hematol Oncol
. 2022 Feb;
41(2):275-284.
PMID: 35195933
We studied the efficacy and safety of the combined treatment with programmed cell death 1 (PD-1) inhibitors and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and subsequent PD-1 inhibitor maintenance...
8.
Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, et al.
Front Immunol
. 2021 Aug;
12:720571.
PMID: 34421924
Clinical Trial Registration: http://www.chictr.org.cn/index.aspx, identifiers ChiCTR1800017051 and ChiCTR2000033925.
9.
Zhu H, Deng H, Mu J, Lyu C, Jiang Y, Deng Q
Onco Targets Ther
. 2021 Jul;
14:4023-4037.
PMID: 34239307
Background: To observe efficacy of the anti-CD22 chimeric antigen receptor modified (anti-CD22-CAR) T cell salvage therapy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and B cell acute lymphoid leukemia...
10.
Liu M, Deng H, Mu J, Li Q, Pu Y, Jiang Y, et al.
Cancer Sci
. 2021 May;
112(7):2642-2651.
PMID: 33932067
The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in...